Intranasal oxytocin ( DrugBank: Oxytocin )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
127	前頭側頭葉変性症	4
193	プラダー・ウィリ症候群	5

127. 前頭側頭葉変性症

臨床試験数 : 90 / 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03260920 (ClinicalTrials.gov)	January 31, 2018	19/7/2017	Intranasal Oxytocin for Frontotemporal Dementia	A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia	Frontotemporal Dementia	Drug: Syntocinon	Lawson Health Research Institute	Weston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry Consultants	Active, not recruiting	30 Years	80 Years	All	112	Phase 2	United States;Canada
2	NCT01937013 (ClinicalTrials.gov)	September 12, 2013	3/9/2013	Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia	Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia	Frontotemporal Dementia	Drug: Intranasal oxytocin;Drug: Saline Nasal Mist	Lawson Health Research Institute	Canadian Institutes of Health Research (CIHR)	Completed	30 Years	85 Years	All	52	Phase 2	Canada
3	NCT01386333 (ClinicalTrials.gov)	June 2011	29/6/2011	Safety Study of Intranasal Oxytocin in Frontotemporal Dementia	A Phase I Dose Finding Study of Intranasal Oxytocinin Frontotemporal Dementia, Protocol # FTDOXY10EF ...	Frontotemporal Dementia	Drug: oxytocin;Drug: Saline Nasal Mist	Lawson Health Research Institute	The Consortium of Canadian Centres for Clinical Cognitive Research (C5R)	Completed	30 Years	80 Years	Both	23	Phase 1	Canada
4	NCT01002300 (ClinicalTrials.gov)	September 2009	23/10/2009	Oxytocin and Social Cognition in Frontotemporal Dementia	Investigation of the Effects of Intranasal Oxytocinon Cognition and Emotion Processing in Frontotemp ...	Frontotemporal Dementia;Pick's Disease	Drug: intranasal oxytocin	Lawson Health Research Institute	The Alzheimer Society London and Middlesex	Completed	30 Years	80 Years	Both	24	N/A	Canada

First Previous1Next Last

193. プラダー・ウィリ症候群

臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05298085 (ClinicalTrials.gov)	April 5, 2022	17/3/2022	Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome	Effect of Intranasal Oxytocinon Dysphagia Related to Oropharyngo-oesophageal Dysmotility in Children ...	Prader-Willi Syndrome	Drug: Oxytocin nasal spray;Drug: Placebo	University Hospital, Toulouse	NULL	Active, not recruiting	2 Years	17 Years	All	25	Phase 2/Phase 3	France
2	NCT03245762 (ClinicalTrials.gov)	August 1, 2017	7/8/2017	Intranasal Oxytocin for Infants With Prader-Willi Syndrome	Intranasal Oxytocinfor Treatment of Infants and Children With Prader-Willi Syndrome in Nutritional P ...	Prader-Willi Syndrome	Drug: Oxytocin;Drug: Placebo	University of Florida	Prader-Willi Syndrome Association	Completed	N/A	6 Months	All	15	Phase 1/Phase 2	United States
3	NCT02629991 (ClinicalTrials.gov)	October 2015	18/10/2015	Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syn ...	Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syn ...	Prader-Willi Syndrome;Hyperphagia	Drug: Intranasal Oxytocin (IN-OXT);Drug: Matched Placebo	Montefiore Medical Center	Foundation for Prader-Willi Research	Unknown status	5 Years	18 Years	All	24	Phase 2	United States
4	NCT02013258 (ClinicalTrials.gov)	March 2015	11/12/2013	Oxytocin Trial in Prader-Willi Syndrome	Oxytocin Trial in Prader-Willi Syndrome	Prader Willi Syndrome	Drug: Intranasal oxytocin;Other: Placebo	University of Florida	National Institutes of Health (NIH)	Completed	5 Years	11 Years	All	24	Phase 1	United States
5	EUCTR2021-000094-91-FR (EUCTR)		01/04/2021	EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA IN CHILDREN AND ADOLESCENTS WITH PRADER WILLI SYNDROME	EFFECT OF INTRANASAL OXYTOCINON DYSPHAGIA RELATED TO OROPHARYNGO-OESOPHAGEAL DYSMOTILITY TRANSIT IN ...	Prader-Willi Syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: OXYTOCIN Product Code: H01BB02	Toulouse University Hospital	NULL	NA			Female: yes Male: yes	36	Phase 3	France

First Previous1Next Last

先頭へ